CAI國際 CAI 深 滬
等待開盤 05-19 09:30:00 美东时间
15.10
+0.550
+3.78%
華盛通- 最 高15.70
- 今 開14.75
- 成交量 544.12万股
- 最 低 14.74
- 昨 收 14.55
- 總市值 42.68亿
- 52周最高 42.50
- 市盈率 靜 --
- 換手率 1.92%
- 52周最低 14.19
- 委 比 91.34%
- 總股本 2.83亿
- 歷史最高 42.50
- 量 比 1.24
- 振 幅 6.60%
- 歷史最低 14.19
- 每 手 1
- 風險率 5.72%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Caris Life Sciences Announces Publication Of A Caris‑Led Study In The Oncologist The Shows Its Lookback Program's Ability To Identify Previously-Profiled Patients Who Become Eligible For Newly Approved Targeted Therapies
Molecular profiling reports from most labs are static, reflecting clinical knowledge only at the time of testing. As new biomarker–drug associations and therapeutic indications emerge, patients with previously identified
05-15 20:36
美股大行评级 | 爱彼迎、Affirm、CoreWeave、Datadog、微芯科技等获多家大行上调目标价；HubSpot惨遭14家大行下调目标价
今日重点评级关注：HC Wainwright & Co.：维持Artiva Biotherapeutics"买入"评级，目标价从15美元升至35美元；韦德布什：维持Cullinan Therapeutics"跑赢大市"评级，目标价从36美元升至37美元
05-11 15:43
BTIG Maintains Buy on Caris Life Sciences, Lowers Price Target to $32
BTIG analyst Mark Massaro maintains Caris Life Sciences (NASDAQ:CAI) with a Buy and lowers the price target from $38 to $32.
05-08 18:36
Caris Life Sciences shares are trading lower. The company reported Q1 financial results.
Caris Life Sciences shares are trading lower. The company reported Q1 financial...
05-08 05:04
Caris Life Receives MolDX Approval For Caris ChromoSeq
Caris Life Sciences® (NASDAQ:CAI), a leading, patient‑centric, next‑generation AI TechBio company and precision medicine pioneer, today announced that Caris ChromoSeq™ has received MolDX approval, a key
05-04 20:37
Calamos Unveils CAGE To Bring Autocallable Growth Strategies To Mainstream Investors
Calamos launches CAGE, an autocallable growth ETF targeting 23% returns with tax-efficient, reinvested coupons.
04-17 05:00
美股大行评级 | 大摩上调哔哩哔哩目标价从25美元升至31美元；大砍近50%！汇丰下调耐克目标价从90美元降至48美元
今日重点评级关注：HC Wainwright & Co.：维持Solaris Resources"买入"评级，目标价从16美元升至18美元；Leerink Partners：维持Spyre Therapeutics"跑赢大市"评级，目标价从49美元升至106美元
04-14 10:44
Jefferies Initiates Coverage On Caris Life Sciences with Buy Rating, Announces Price Target of $28
Jefferies analyst Tycho Peterson initiates coverage on Caris Life Sciences (NASDAQ:CAI) with a Buy rating and announces Price Target of $28.
04-13 20:24
